Express Pharma

OCTOBER 16, 2024

Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally.

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

European Pharmaceutical Review

APRIL 26, 2024

“approval [of Pyzchiva ® (biosimilar ustekinumab)] of is a crucial step towards offering European patients an additional safe and effective treatment option” Pharmaceutical company Sandoz has announced that the European Commission (EC) has granted marketing authorisation for Pyzchiva ® (biosimilar ustekinumab ).

Biosimilars 98

Biosimilars Packaging Pharmaceutical Companies Pharmaceutical Companies 98

Express Pharma

JULY 30, 2024

Zydus Life Sciences is engaged in a legal battle with Roche over its biosimilar, Sigrima, which is based on Roche’s Perjeta (Pertuzumab), targeting the human epidermal growth factor receptor 2-positive (HER2+) breast cancer market in India. per cent from 114,393 in 2024 to 139,486 in 2033.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105

PharmaShots

MARCH 29, 2023

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunity 49

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2024 [cited 2024May]. Available from: [link] Legislation [Internet].

Drug Development 103

Drug Development Biosimilars Documentation Compounding 103

Express Pharma

SEPTEMBER 3, 2024

Listed pharma companies in India have been reporting on their ESG initiatives for the past few years. Quoting from the EY-CII 2024 report ‘How can Sustainability and ESG be the microscope and telescope in the Indian healthcare sector? The company agreed to meet certain sustainability targets that helped reduce the cost of the loan.

Packaging 111

Packaging Biosimilars Communication Pharmaceutical Companies 111

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Pharmaceutical Technology

JUNE 15, 2023

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

Biosimilars 52

Biosimilars Communication Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52